After initially serving as a proving ground for integrating forward engineering principles into living cells, synthetic biology is making waves across diverse therapeutic areas. In this article, Dr. Dan Mandell, Co-Founder and CEO of GRO Biosciences, explains how the field is reshaping our understanding of the limits of cell- and molecular-based medicines.
AIChE: Catalyzing Commercialization: Redefining Protein Therapeutics with an Expanded Amino Acid Universe
Chemical & Engineering News: Gro Biosciences raises $25 million to make protein therapies from genetically recoded organisms
George Church discusses the biotechnology underpinning GRO Biosciences Inc., which could provide a workaround for some well-known problems in protein therapeutics. The startup just hauled in millions to tackle those problems.
Endpoints: Bayer backs a George Church spinout trying to turn lab-invented amino acids into a new class of protein therapies
Beyond Meat (BYND) was one of last year’s hottest stocks. Shares of the plant-based meat company exploded 859% during its first three months out of the gate.
In the early 2000s, Jay Shendure was a graduate student in George Church’s lab at Harvard University. Back then, he says, there was “hardly an inkling” that the lab would become a hotbed of startup activity.
“DNA is like a computer program but far, far more advanced than any software ever created.”
Bill Gates wrote this in 1995, long before synthetic biology – a scientific discipline focused on reading, writing, and editing DNA – was being harnessed to program living cells.
By altering the genetic code in bacteria, researchers have demonstrated a method to make therapeutic proteins more stable, an advance that would improve the drugs’ effectiveness and convenience.
A year ago, a group of scientists convened in New York City to discuss an audacious plan: construct an entire human genome from scratch.
To uncover the mission of GRO Biosciences Inc., one has to look no further than its name. The acronym stands for “genomically recoded organisms”
Harvard geneticist and serial biotech entrepreneur George Church has co-founded a new startup that aims to develop “designer proteins” targeting a range of disorders.
GRO Biosciences Inc. wants to make a giant sector in the pharmaceutical industry even larger. The spinout from the lab of Harvard Medical School geneticist George Church aims to make protein drugs more versatile and effective
Biology is computation. It operates on the digital alphabet of biochemistry, which is quite a bit more complicated than binary, hex, or even Haskell.
GRO Biosciences Announces Appointment of Bruce Beutel, PhD to Board of Directors and J.P. Morgan Health Care Conference Week Activities
GRO Biosciences Strengthens Management Team With Appointment of Veteran Biotechnology Executive, Edward Stewart as Chief Business Officer
BOSTON, November 3, 2021 – GRO Biosciences Inc. (“GRObio”), an emerging biotechnology company leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced the closing of a Series A financing
BOSTON, Sept. 28, 2017 – GRO Biosciences Inc. today announced that the company has secured $2.1 million in a seed funding round co-led by Digitalis Ventures and Eric Schmidt’s Innovation Endeavors.
Aditya M Kunjapur, Michael G Napolitano, Eriona Hysolli, Karen Noguera, Evan M Appleton, Max G Schubert, Michaela A Jones, Siddharth Iyer, Daniel J Mandell, George M Church. Synthetic auxotrophy remains stable after continuous evolution and in coculture with mammalian cells. Sci Adv, 2021 Jul (27):eabf5851. doi: 10.1126/sciadv.abf5851. Print 2021 Jul.https://pubmed.ncbi.nlm.nih.gov/34215581/
Feiner R, Kemker I, Krutzke L, Allmendinger E, Mandell DJ, Sewald N, Kochanek S, Müller KM (2020) EGFR-Binding Peptides: From Computational Design towards Tumor-Targeting of Adeno-Associated Virus Capsids. Int. J. Mol. Sci. 21(24):9535.https://www.mdpi.com/1422-0067/21/24/9535
Glasgow AA, Huang YM, Mandell DJ, Thompson M, Ritterson R, Loshbaugh AL, Pellegrino J, Krivacic C, Pache RA, Barlow KA, Ollikainen N, Jeon D, Kelly MJS, Fraser JS, Kortemme T (2019) Computational design of a modular protein sense-response system. Science, 366(6468):1024-1028. PMID: 31754004.https://www.science.org/doi/full/10.1126/science.aax8780
Thyer R, Shroff R, Klein DR, d'Oelsnitz S, Cotham VC, Byrom M, Brodbelt J, Ellington A (2018) Custom selenoprotein production enabled by laboratory evolution of recoded bacterial strains. Nature Biotechnology, EPub ahead of print.https://www.nature.com/articles/nbt.4154
Ostrov N, Landon M, Guell M, Kuznetsov G, Teramoto J, Cervantes N, Zhou M, Singh K, Napolitano MG, Moosburner M, Shrock E, Pruitt BW, Conway N, Goodman DB, Gardner C, Tyree G, Gonzales A, Wanner BL, Norville J, Lajoie MJ, Church GM (2016) Design, Synthesis and Testing Towards a 57-Codon Genome. Science 353(6301):819-22. PMID: 27540174https://pubmed.ncbi.nlm.nih.gov/27540174/
Lajoie MJ, Rovner AJ, Goodman DB, Aerni HR, Haimovich AD, Mercer JA, Wang HH, Carr PA, Mosberg JA, Rohland N, Schultz PG, Jacobson JM, Rinehart J, Church GM, Isaacs FI (2013) Genomically Recoded Organisms Impart New Biological Functions. Science 342: 357-60. PMID: 24136966https://pubmed.ncbi.nlm.nih.gov/24136966/